Hey all, welcome back to the Real Life Pharmacology podcast. I'm your host pharmacist, Eric Christensen.

Thank you so much for listening today. As always, head over to reallife pharmacology.com.

Check out the free 31-page PDF on the top 200 drugs. A great little resource for students and practicing healthcare professionals alike.

I've put in my most important clinical pearls for the top 200 drugs.

So definitely go check that out.

Take advantage of that for free.

And we get you updates when we've got a new podcast and content available.

All right. So let's talk about the drug of the day today. I am going to talk about cyclosporin. And if you remember in the

previous few weeks there, I did talk about tachrolomus. So a lot of the information is going to be overlapping. They are from the same classification.

They are both considered calcineurin inhibitors and of course immunosuppressives there as well.

But there are a few differences that I wanted to point out, one particularly, with regard to dosage form.

So cyclosporin has some really, really important warnings regarding experienced physicians,

and especially if we're considering changing from one dosage form to another,

they are generally not considered interchangeable, and you could run the risk,

depending upon which one you're switching to, run the risk of toxicity or potentially

subtherapeutic dosing. So common brand names that I've heard used with the use of cyclosporne,

Gengraph, Neural, Sandimmune.

And again, remember, Kelsenurin inhibitors, really work on that adaptive

immunity side of things and inhibit the activation of T lymphocytes.

And I went into a little bit more detail under the Ticrolomus section.

So if you want to go back and listen to that podcast, I talk a little bit more in depth about

the mechanism of action.

...